Prenatal testing sits at the intersection of medical information and deeply personal decision-making, and the range of options available to pregnant individuals has expanded enough that the choices between them are not always obvious from the outside. Two of the most well-established diagnostic tests in prenatal medicine, chorionic villus sampling and amniocentesis, are sometimes grouped together in conversation as though they are essentially the same procedure with minor variations. They are not. They differ in what they sample, when in pregnancy they are performed, what they can detect, and what the procedural risks look like, and understanding those differences matters for anyone considering them.
This distinction is worth covering separately from the question of non-invasive options, which operate on different principles and serve different purposes in the prenatal testing pathway.
What Each Procedure Involves and When It Is Done
Chorionic villus sampling, commonly referred to as CVS, involves taking a small sample of placental tissue for analysis. The placenta and the developing baby share the same genetic material, which is what makes the placental sample diagnostically useful. CVS is typically performed between ten and thirteen weeks of pregnancy, which makes it one of the earliest diagnostic options available for chromosomal and genetic conditions. The procedure can be performed either through the abdomen or through the cervix depending on the position of the placenta and the clinical judgment of the specialist performing it.
Amniocentesis involves taking a sample of the amniotic fluid that surrounds the developing baby. The fluid contains cells shed by the baby, and these cells can be analyzed for chromosomal abnormalities and specific genetic conditions. Amniocentesis is typically performed from around fifteen weeks of pregnancy onward, with sixteen to twenty weeks being the most common window. The procedure is performed through the abdomen under ultrasound guidance, with a fine needle used to withdraw the fluid sample.
The timing difference between the two is significant for families who need diagnostic information early in a pregnancy, either for medical planning purposes or for other personal reasons. CVS provides information several weeks earlier than amniocentesis, which is one of the primary reasons it may be recommended or chosen over the later procedure. Amniocentesis, by contrast, has a longer established history of use and a slightly different risk and result profile that makes it the preferred option in certain clinical situations.
The question of non-invasive prenatal testing and how it connects to the decision about diagnostic procedures is one that comes up regularly in prenatal care conversations. Non-invasive approaches screen for the probability of certain conditions rather than providing a definitive diagnostic result, which is the fundamental distinction between screening and diagnosis in this context. The approach to non invasive genetic testing pregnancy through NIPT is covered through this Medgenome page, which explains how the non-invasive pathway works and when it is used relative to diagnostic options like CVS and amniocentesis.
Risk Profiles and What They Mean in Practice
Both CVS and amniocentesis carry a small risk of pregnancy loss that is associated with the procedure rather than with the underlying condition being tested for. The risk figures cited in clinical literature have been refined over the years as procedural technique has improved, and the risk associated with both procedures in experienced hands is lower now than older published figures sometimes suggest. Discussing the current risk estimates with the specialist performing the procedure, rather than relying on older published data, gives a more accurate picture of what the procedural risk looks like in a specific clinical context.
CVS has the additional consideration that a finding called confined placental mosaicism, where the genetic makeup of the placental sample differs from that of the baby, can occasionally produce a result that does not accurately represent the baby’s chromosomes. This can lead to a result that requires follow-up amniocentesis to confirm, which is a possibility worth understanding before CVS is chosen based on timing alone.
Amniocentesis results typically take longer to return than CVS results in some laboratories, though this varies between institutions and testing approaches. The specific turnaround times for results, and what the results cover in terms of chromosomal and genetic information, are part of the pre-procedure counseling conversation that should happen before either test is agreed to. Anyone navigating this decision as part of a prenatal diagnostic pathway, and looking at the nipt test as a prior or parallel step in that pathway, will find the clinical context for how these options connect on the same Medgenome page.